Kala Bio, Inc. (KALA)
0.595
+0.06
(+10.62%)
USD |
NASDAQ |
Sep 09, 14:39
Kala Bio Enterprise Value : 3.174M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 3.174M |
| September 04, 2026 | 2.582M |
| September 03, 2026 | 3.621M |
| September 02, 2026 | 2.876M |
| September 01, 2026 | 3.064M |
| August 31, 2026 | 5.781M |
| August 28, 2026 | 6.117M |
| August 27, 2026 | 8.477M |
| August 26, 2026 | 8.554M |
| August 25, 2026 | 8.649M |
| August 24, 2026 | 8.154M |
| August 21, 2026 | 8.632M |
| August 20, 2026 | 9.018M |
| August 19, 2026 | 10.18M |
| August 18, 2026 | 10.15M |
| August 17, 2026 | 10.37M |
| August 14, 2026 | 11.06M |
| August 13, 2026 | 10.64M |
| August 12, 2026 | 9.867M |
| August 11, 2026 | 9.111M |
| August 10, 2026 | 7.372M |
| August 07, 2026 | 7.233M |
| August 06, 2026 | 7.021M |
| August 05, 2026 | 6.328M |
| August 04, 2026 | 7.140M |
| Date | Value |
|---|---|
| August 03, 2026 | 7.914M |
| July 31, 2026 | 7.39M |
| July 30, 2026 | 6.883M |
| July 29, 2026 | 5.794M |
| July 28, 2026 | 5.539M |
| July 27, 2026 | 5.740M |
| July 24, 2026 | 5.036M |
| July 23, 2026 | 4.574M |
| July 22, 2026 | 7.015M |
| July 21, 2026 | 6.955M |
| July 20, 2026 | 7.274M |
| July 17, 2026 | 7.775M |
| July 16, 2026 | 9.154M |
| July 15, 2026 | 12.69M |
| July 14, 2026 | 11.40M |
| July 13, 2026 | 13.85M |
| July 10, 2026 | 15.50M |
| July 09, 2026 | 18.88M |
| July 08, 2026 | 19.65M |
| July 07, 2026 | 21.97M |
| July 06, 2026 | 22.55M |
| July 02, 2026 | 25.26M |
| July 01, 2026 | 27.20M |
| June 30, 2026 | 26.23M |
| June 29, 2026 | 30.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.581M |
| Total Expenses (Quarterly) | 1.581M |
| EPS Diluted (Quarterly) | -21.32 |
| Earnings Yield | -12.42K% |
| Normalized Earnings Yield | -16506.55 |